SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

1 year ago

DENVER, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024 

1 year ago

SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel…

Tizona Therapeutics Announces Expansion of Phase 1b Clinical Trial to Evaluate TTX-080 in Combination with EGFR Inhibitor Cetuximab and Chemotherapy in Advanced Colorectal Cancer

1 year ago

Trial builds upon promising evidence of clinical activity of TTX-080 when combined cetuximab, presented at ASCO 2024SOUTH SAN FRANCISCO, Calif.,…

Alkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial Officer

1 year ago

Accomplished Finance and Commercial Leader Brings Extensive Life Sciences ExpertiseCAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc.…

New Treatments, Novel Research Drive Better Survival Rates for Canadians with Lung Cancer, Offering Hope to Thousands: Lung Health Foundation

1 year ago

Lung Cancer Awareness Month: Survivors Share Stories of Hope and Resilience Amid Revolutionary Medical BreakthroughsTORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE)…

Edesa Biotech’s Founder Makes Strategic Investment in the Company

1 year ago

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics…

Bionano Adjourns Special Meeting of Stockholders to November 27, 2024

1 year ago

Special Meeting of Stockholders Adjourned Due to Lack of QuorumSAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.…

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

1 year ago

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling…

MaxCyte to Participate in Two Upcoming Investor Conferences

1 year ago

ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing…